Showing 71-80 of 3239 results for "".
- New Sunscreen Blocks UV Rays, Boosts Vitamin Dhttps://practicaldermatology.com/news/new-sunscreen-blocks-rays-boosts-vitamin-d/2458724/A new sunscreen may do more than block ultraviolet radiation, it may also allow the body to produce vitamin D. The sunscreen, Solar D, is currently available in Australia and will be available in the U.S. in summer 2016.The
- New Web Tool May Curb Indoor Tanning Use Among Coedshttps://practicaldermatology.com/news/new-web-tool-may-curb-indoor-tanning-use-among-coeds/2458737/A web-based intervention that taps into indoor tanning users’ perceptions about the value of tanning may help curb tanning bed use among young females, suggests research out of Rutgers Cancer Institute of New Jersey in New Brunswick. Research has shown that some indoor tanners do so
- CareCredit Hosts Free Webinar on How to Host Successful Patient Eventshttps://practicaldermatology.com/news/carecredit-hosts-free-webinar-on-how-to-host-successful-patients-events/2458975/CareCredit will be sponsoring a free webinar to all aesthetic providers on how to host successful patient events. The webinar, How to Host Events That Bring Real Results: The Dos, Don’ts, and Definites, will be presented by Karen Zupko, President of Karen Zupko & Associate
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- Fish Oil With Low-Dose Isotretinoin Shows Noninferior Acne Controlhttps://practicaldermatology.com/news/fish-oil-with-low-dose-isotretinoin-shows-noninferior-acne-control/2488054/Fish oil supplementation added to low-dose isotretinoin was noninferior to isotretinoin alone for reducing acne lesions and may help preserve skin hydration and limit increases in triglyceride levels, according to findings published in the
- High-Dose Vitamin D May Ease Chemotherapy- and Radiation-Related Skin Toxicities: Analysishttps://practicaldermatology.com/news/high-dose-vitamin-d-may-ease-chemotherapy-and-radiation-related-skin-toxicities/2487809/High-dose oral vitamin D may offer an option for patients experiencing chemotherapy- and radiation-induced skin toxicities, according to a multicenter case series published in JAMA Dermatology.
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and